Procyrion Expands Office Space in Preparation for Commercialization and Growing Team


HOUSTON, TX (November 4th, 2016) - Houston heart pump developer Procyrion Inc. today announced the expansion of their office to support their growth and the further development of their ground breaking technology, Aortix™, a catheter-based circulatory support device. The new office space will provide capacity for increased research and development, lab space, and leadership functions across the company.

Procyrion continues to co-locate with founding investor Fannin Partners, LLC.  The combined entities now occupy almost 4,500 square feet of office and lab space. Located at 3900 Essex Lane, Suite 575, in Houston, Procyrion’s office space has now doubled in size, going from six offices to eleven, includes a machine shop, dry lab, wet lab, and an electronics lab. The office features a smartly configured floor plan designed to promote productivity in a collaborative environment.

“Procyrion’s new office space not only fits our strategic needs, but gives us a fresh, new landscape for building on our capabilities in key areas that align with our current and future growth plans,” said Benjamin A. Hertzog, Ph.D., CEO of Procyrion. “We knew it was vital to create a well-designed space for our team to support their success as we work towards commercialization.”

Procyrion’s award-winning technology, Aortix™, which is thinner than a #2 pencil, is the first catheter-based heart pump designed specifically for the ambulatory treatment of NYHA Class III-IVa heart failure patients who are too sick for medication alone, but not sick enough for risky surgical interventions (e.g. LVAD or transplant). The small but powerful micro pump is placed downstream of the heart in a simple cath-lab procedure and works to support heart function by accelerating native blood flow.

Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use.  The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients.  For more information, visit or call 713.579.9227.

Read More